ACAD FY 2012 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

FY 2012 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+137.4% YoY

Gross Profit

-$14M-283.0% margin

Operating Income

-$21M-425.6% margin

Net Income

-$21M-424.9% margin

EPS (Diluted)

$-0.38

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$109M

Total Liabilities

$24M

Stockholders' Equity

$85M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$2M	+137.4%
Gross Profit	-$14M	$2M	-771.8%
Operating Income	-$21M	-$23M	+8.6%
Net Income	-$21M	-$23M	+8.4%